

GLOBAL BIOPHARMA CEO / TOP EXECS COVID-19 PRESS BRIEFING

COVID-19 diagnostics, treatments and vaccines: Progress achieved in 2020 and insights into 2021 and beyond

When: Tuesday, 8th December 2020, 2:30 PM – 4:00 PM CET - Geneva / 8:30 AM –10:00 AM EDT - New York

Organised by the International Federation of Pharmaceutical Manufacturers and Associations ([IFPMA](#)) – representing the global innovative biopharmaceutical industry [committed](#) to addressing [the novel coronavirus public health crisis](#).

Speaker line-up:

- **Eli Lilly and Company:** David A. Ricks, Chairman and Chief Executive Officer & President of IFPMA
- **GlaxoSmithKline:** Roger Connor, President Global Vaccines
- **Johnson & Johnson:** Dr Paul Stoffels, Vice-Chairman of the Executive Committee and Chief Scientific Officer
- **Pfizer:** Dr Albert Bourla, Chairman and Chief Executive Officer
- **Roche Group:** Dr Severin Schwan, Chief Executive Officer & Vice-President IFPMA
- **IFPMA:** Thomas Cueni, Director General, IFPMA

Press briefing format:

- Dataset - Airfinity COVID-19 data on R&D pipeline COVID-19 vaccines and therapeutics pipeline, approvals, deals & vaccine commitments countries and prices; vaccine logistical challenges.
- CEO & top executive statements, followed by journalist question time.
- Questions on dataset to be submitted by chat and answered by Airfinity live.

Sign-in guidance:

- Journalists are invited to **register their interest in joining using [this link](#)**. Once your interest is registered, you will receive a link to the platform for the media briefing on Monday, 7 December.
- Questions sent before Tuesday 8th December, 09:00 CET at a.jones@ifpma.org will be given priority.
- Questions during the briefing can be submitted using the chat function on the platform.
- When signing on to the platform, please type in your Name Surname and Media Outlet, which will allow us to follow-up on your question should it not be possible to cover it during the briefing itself.
- Journalists will be able to download media materials and the press release on the platform when they sign in (these will be under embargo until 2:30 PM CET when the briefing starts).

The recording will be made available on the [IFPMA YouTube page](#) and all press materials will be published on www.ifpma.org.

For more information, please see:

- [IFPMA COVID-19 Information Hub](#), with examples of how the biopharmaceutical industry is leading the way in developing vaccines, treatments and diagnostics.
- [Industry Commitment](#): “Global Biopharmaceutical Industry Commitment to Address Coronavirus Public Health Crisis”.
- [Full videos](#) of the past IFPMA COVID-19 press briefings.

Note to editors:

[IFPMA](#) ([@IFPMA](#)) represents research-based biopharmaceutical companies and associations across the globe. The research-based pharmaceutical industry's 2 million employees research, develop and provide medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.

Press contacts

Abigail Jones

a.jones@ifpma.org

+32 475 41 09 76

Morgane De Pol

m.depol@ifpma.org

+41 79 962 11 95

Paloma Tejada

p.tejada@ifpma.org

+41 79 874 44 25

